UK Influenza Vaccine Market Size & Outlook, 2023-2030
UK influenza vaccine market, 2018-2030 (US$M)
Related Markets
UK influenza vaccine market highlights
- The UK influenza vaccine market generated a revenue of USD 283.1 million in 2023 and is expected to reach USD 430.2 million by 2030.
- The UK market is expected to grow at a CAGR of 6.2% from 2024 to 2030.
- In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
- Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Influenza vaccine market data book summary
| Market revenue in 2023 | USD 283.1 million |
| Market revenue in 2030 | USD 430.2 million |
| Growth rate | 6.2% (CAGR from 2023 to 2030) |
| Largest segment | Inactivated |
| Fastest growing segment | Inactivated |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inactivated, Live Attenuated |
| Key market players worldwide | GSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines |
Other key industry trends
- In terms of revenue, UK accounted for 3.6% of the global influenza vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
- Denmark is the fastest growing regional market in Europe and is projected to reach USD 31.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Vaccine Market Scope
Influenza Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK influenza vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza vaccine market will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 91.7% in 2023. Horizon Databook has segmented the UK influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
The influenza vaccine market in UK is one of the major markets in the region. High vaccine uptake against the flu, better immunization programs, favorable government initiatives, and increased R&D activities in the country are driving the market growth. In addition, high disease burden and significant government interventions in vaccination programs are some of the factors driving the market.
For instance, in September 2018, Public Health England announced new flu vaccination recommendations for individuals aged more than 65. The authority recommended the adjuvanted trivalent influenza vaccine to people with higher influenza risk.
Moreover, the ongoing collaborations between leading participants and governments to maintain a robust vaccine supply is propelling the growth forward. For instance, in December 2022, Moderna announced its plans to invest in mRNA R&D in the UK and establish a new vaccine development center with a capacity of manufacturing up to 250 million vaccines a year.
Reasons to subscribe to UK influenza vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK influenza vaccine market databook
-
Our clientele includes a mix of influenza vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK influenza vaccine market , including forecasts for subscribers. This country databook contains high-level insights into UK influenza vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK influenza vaccine market size, by vaccine type, 2018-2030 (US$M)
UK Influenza Vaccine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
